CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company developing treatments for primary and metastatic cancers of the brain and central nervous system, reported a leadership transition under which John Climaco has stepped down as chief executive officer and Rami Levin, MBA, has been appointed president and chief executive officer, effective Jan. 1, 2026. Levin brings nearly three decades of global leadership experience across oncology, neurology and rare diseases, with a track record of advancing late-stage clinical programs, scaling organizations and leading strategic turnarounds, positioning CNS to advance its pipeline and next phase of development.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://nnw.fm/CNSP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer